eligibility_summary
Eligible: adults (≥18) with histologically confirmed advanced/metastatic CD70+ solid tumors after ≥2 lines failed or lacking standard 1st-line, ≥1 measurable lesion (RECIST 1.1), ECOG 0–1, life expectancy >12 wks, adequate marrow/renal/hepatic/coagulation, contraception for 6 months. Exclude: prior anti‑CD70, recent chemo/targeted or high‑dose steroids, pregnancy, active HBV/HCV/HIV/syphilis/CMV, serious cardiac disease, active CNS mets, prior organ/allo‑HSCT, recent vaccines, other active cancers, uncontrolled illness, per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CHT101, an allogeneic, off‑the‑shelf anti‑CD70 UCAR‑T cell therapy (genetically engineered T‑cell immunotherapy) administered after lymphodepleting chemotherapy with fludarabine (purine‑analog antimetabolite) and cyclophosphamide (alkylating agent). Mechanism of action: CAR‑modified T cells recognize and bind CD70 on tumor cells, triggering T‑cell activation, cytotoxic killing, and cytokine release, lymphodepletion reduces host lymphocytes and supports CAR‑T expansion/persistence. Targets (cells/pathways): CD70 (TNFSF7) expressed on solid tumors (e.g., renal cell carcinoma, head & neck SCC, nasopharyngeal, ovarian, cervical), disrupting the CD70 axis and engaging CAR‑T effector pathways to induce tumor cell death. Design: Phase 1, single‑arm dose escalation/expansion (3×10^6–1×10^7 cells/kg) to assess safety and define dose.